{"nctId":"NCT00051168","briefTitle":"A Long-term Safety Study of Once-daily Travatan","startDateStruct":{"date":"2006-01"},"conditions":["Glaucoma, Open-angle","Ocular Hypertension"],"count":502,"armGroups":[{"label":"Travatan","type":"EXPERIMENTAL","interventionNames":["Drug: Travatan"]}],"interventions":[{"name":"Travatan","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Adult patients of any race and either sex with chronic angle-closure glaucoma.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Intraocular Pressure","description":"Mean IOP for the patient's worse eye at baseline was used in the secondary endpoint analysis. 2 consecutive IOP measurements for each eye were taken. If the 2 measurements for the same eye differ by 4 mmHg or less, the average of the measurements would be considered as the mean IOP for that eye. If the 2 measurements for the same eye differ by more than 4 mmHg, then a third measurement was to be taken.\n\nAll IOP measurements were performed with a Goldmann applanation tonometer.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":"2.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":99,"n":502},"commonTop":["Iris hyperpigmentation","Cataract","Hypertension","Visual acuity reduced","Ocular hyperemia"]}}}